vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v15i1.1504vsp-1586Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEПрименение ингибитора интерлейкина 1 канакинумаба у детей с аутовоспалительными заболеваниями и системным ювенильным артритом: описание серии случаевAdministration of the Interleukin-1 Inhibitor Canakinumab in Children with Autoinflammatory Diseases and Systemic Juvenile Arthritis: the Report for Case SeriesСалугинаС. О.SaluginaS. O.

доктор медицинских наук, ведущий научный сотрудник лаборатории ревматических заболеваний детского возраста,

115522, Москва, Каширское ш., д. 34А

Moscow

pafon1@yandex.ruКаледаМ. И.KaledaM. I.

Москва

Moscow

ФёдоровЕ. С.FyodorovYe. S.

Москва

Moscow

НикишинаИ. П.NikishinaI. P.

Москва

Moscow

НИИ ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2016240220161518794Copyright © Салугина С.О., Каледа М.И., Фёдоров Е.С., Никишина И.П., 20162016Салугина С.О., Каледа М.И., Фёдоров Е.С., Никишина И.П.Salugina S.O., Kaleda M.I., Fyodorov Y.S., Nikishina I.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1586

В России для лечения аутовоспалительных заболеваний и системного ювенильного артрита (сЮА) все чаще используют ингибитор интерлейкина 1 канакинумаб (полностью человеческие моноклональные антитела к интерлейкину 1). В статье представлено описание опыта применения канакинумаба у пациентов с аутовоспалительными заболеваниями (n = 12) и сЮА (n = 7), проанализированы эффективность и переносимость препарата. Канакинумаб назначали подкожно, в дозе 2–6 мг/кг (максимально 300 мг) 1 раз в 4–8 нед. Продолжительность терапии составила от 3 мес до 4 лет. У всех пациентов отмечено быстрое клиническое улучшение, купирование системных проявлений, нормализация уровня острофазовых маркеров воспаления. У 4 пациентов с сЮА не удалось добиться купирования проявлений артрита. Серьезных нежелательных явлений при применении препарата не зарегистрировано. Таким образом, опыт применения канакинумаба у пациентов с аутовоспалительными заболеваниями и сЮА показал высокую эффективность и хорошую переносимость препарата. Применение канакинумаба при сЮА может быть эффективно на ранних этапах заболевания у пациентов с системными и начальными суставными изменениями.

In Russia, the interleukin-1 inhibitor canakinumab (fully human monoclonal antibodies to interleukin-1) is increasingly used for treating autoinflammatory diseases and systemic juvenile arthritis (sJIA). The article describes the experience of administering canakinumab in patients with autoinflammatory diseases (n = 12) and sJIA (n = 7), the efficacy and tolerability of the drug are analyzed. Canakinumab was prescribed subcutaneously in a dose of 2–6 mg/kg (maximum 300 mg) once in 4–8 weeks. The therapy duration ranged from 3 months to 4 years. All patients had a rapid clinical improvement, relief of systemic manifestations, normalization of the level of acutephase inflammatory markers. In 4 patients with sJIA we failed to achieve the relief of arthritis symptoms. While administering the drug, no serious adverse events were registered. Thus, the experience of administering canakinumab in patients with autoinflammatory diseases and sJIA showed the high efficacy and good tolerability of the drug. The canakinumab administration at sJIA can be effective in the early disease stages in patients with systemic and initial articular changes.

аутовоспалительные заболеваниясистемный ювенильный артритлечениеингибиторы интерлейкина 1канакинумабautoinflammatory diseasessystemic juvenile arthritistreatmentinterleukin-1 inhibitorscanakinumabкомпания «Новартис Фарма»ReferencesFietta P. Autoinflammatory disease: the hereditary periodic fever syndromes. Acta Biol Ateneo Parmense. 2004;75:92–99.Fietta P. Autoinflammatory disease: the hereditary periodic fever syndromes. Acta Biol Ateneo Parmense. 2004;75:92–99.Кузьмина НН, Салугина СО, Федоров ЕС. Аутовоспалительные заболевания и синдромы у детей. Учебно-методическое пособие. М.: ИМА–ПРЕСС. 2012. 104 с.Кузьмина НН, Салугина СО, Федоров ЕС. Аутовоспалительные заболевания и синдромы у детей. Учебно-методическое пособие. М.: ИМА–ПРЕСС. 2012. 104 с.Гатторно М. Аутовоспалительные заболевания у детей. Вопросы современной педиатрии. 2014;13(2):55–64.Гатторно М. Аутовоспалительные заболевания у детей. Вопросы современной педиатрии. 2014;13(2):55–64.Barron K, Kastner D. Periodic fever syndromes and other inherited autoinflammatory diseases in: Textbook of pediatric rheumatology. Ed. RE Petty. 7th ed. Philadelphia: Saunders Elsevier. 2015. Р. 609–626.Barron K, Kastner D. Periodic fever syndromes and other inherited autoinflammatory diseases in: Textbook of pediatric rheumatology. Ed. RE Petty. 7th ed. Philadelphia: Saunders Elsevier. 2015. Р. 609–626.Caso F, Rigante D, Vitale A, Lucherini OM, Costa L, Atteno M, Compagnone A, Caso P, Frediani B, Galeazzi M, Punzi L, Cantarini L. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol. 2013;2013:513782.Caso F, Rigante D, Vitale A, Lucherini OM, Costa L, Atteno M, Compagnone A, Caso P, Frediani B, Galeazzi M, Punzi L, Cantarini L. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol. 2013;2013:513782.Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L, Frenkel J, Anton J, Kone-Paut I, Cattalini M, Bader-Meunier B, Insalaco A, Hentgen V, Merino R, Modesto C, Toplak N, Berendes R, Ozen S, Cimaz R, Jansson A, Brogan PA, Hawkins PN, Ruperto N, Martini A, Woo P, Gattorno M. The phenotype of TNF receptorassociated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2014;73:2160–2167. Doi:10.1136/annrheumdis-2013-204184368.Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L, Frenkel J, Anton J, Kone-Paut I, Cattalini M, Bader-Meunier B, Insalaco A, Hentgen V, Merino R, Modesto C, Toplak N, Berendes R, Ozen S, Cimaz R, Jansson A, Brogan PA, Hawkins PN, Ruperto N, Martini A, Woo P, Gattorno M. The phenotype of TNF receptorassociated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2014;73:2160–2167. Doi:10.1136/annrheumdis-2013-204184368.Cantarini L, Lucherini OM, Muscari I, Frediani B, Galeazzi M, Brizi MG, Simonini G, Cimaz R. Tumor necrosis factor receptor — associated syndrome (TRAPS): State of the art and future perspectives. Autoimmun Rev. 2012;12:38–43. Doi: 10.1016/j.autrev.2012.07.020Cantarini L, Lucherini OM, Muscari I, Frediani B, Galeazzi M, Brizi MG, Simonini G, Cimaz R. Tumor necrosis factor receptor — associated syndrome (TRAPS): State of the art and future perspectives. Autoimmun Rev. 2012;12:38–43. Doi: 10.1016/j.autrev.2012.07.020Литвицкий ПФ. Патофизиология. Т. 1. М.: ГЭОТАР-Медиа. 2003. С. 142.Литвицкий ПФ. Патофизиология. Т. 1. М.: ГЭОТАР-Медиа. 2003. С. 142.Simon A, van der Meer JWS. Pathogenesis of familial periodic fever syndromes or hereditary inflammatory syndromes. Am J Physiol Regul Integr Comp Physiol. 2007;292:86–98.Simon A, van der Meer JWS. Pathogenesis of familial periodic fever syndromes or hereditary inflammatory syndromes. Am J Physiol Regul Integr Comp Physiol. 2007;292:86–98.Goldbach-Mansky R, Kastner DL. Autoinflammation: The prominent role of IL-1 in monogenic autoinflammatory diseases and implication for common illnesses. J Allergy Clin Immunol. 2009;124:1141–1151.Goldbach-Mansky R, Kastner DL. Autoinflammation: The prominent role of IL-1 in monogenic autoinflammatory diseases and implication for common illnesses. J Allergy Clin Immunol. 2009;124:1141–1151.Dinarello C. A Signal for the Caspase-1 Inflammasome Free of TLR. Immunity. 2007;26:383–385.Dinarello C. A Signal for the Caspase-1 Inflammasome Free of TLR. Immunity. 2007;26:383–385.Drenth JPH, van der Meer WM. The Inflammasome A Linebacker of Innate Defense. N Engl J Med. 2006;355:730–732.Drenth JPH, van der Meer WM. The Inflammasome A Linebacker of Innate Defense. N Engl J Med. 2006;355:730–732.Zimmer S, Grebe A, Latz E. Circ Res. 2015;116:323–340.Zimmer S, Grebe A, Latz E. Circ Res. 2015;116:323–340.Galon J, Aksentijevich I, Mc Dermott F, O`Shea JJ, Kastner DL. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol. 2000;12:479–486.Galon J, Aksentijevich I, Mc Dermott F, O`Shea JJ, Kastner DL. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol. 2000;12:479–486.Takei S. Systemic JIA as an Autoinflammatory Disease. Inflamm Regener. 2011;31;1:52–65.Takei S. Systemic JIA as an Autoinflammatory Disease. Inflamm Regener. 2011;31;1:52–65.Federici S, Martini A, Gattorno M. The central role of antiIL-1 blockade in the treatment of monogenic and multifactorial autoinflammatory diseases. Frontiers un Immunology. 2013;4:351.Federici S, Martini A, Gattorno M. The central role of antiIL-1 blockade in the treatment of monogenic and multifactorial autoinflammatory diseases. Frontiers un Immunology. 2013;4:351.Kuemmerle-Deschner J, Haug I. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. Ther Adv Musculoskel Dis. 2013;5(6):315–319.Kuemmerle-Deschner J, Haug I. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. Ther Adv Musculoskel Dis. 2013;5(6):315–319.Toker O, Hashkes PJ. Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS). Biologics: Targets & Therapy. 2010;4:131–138.Toker O, Hashkes PJ. Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS). Biologics: Targets & Therapy. 2010;4:131–138.Lachmann H, Kone-Paut I, Kuemmerle-Deschner GB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN. Use for the Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–2425.Lachmann H, Kone-Paut I, Kuemmerle-Deschner GB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN. Use for the Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–2425.Kuemmerle-Deschner JB, Hachulla E, Gartwright R, Hawkins PN, Tran TA. Two year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of Canakinumab in pts with cryopyrin associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70(12):2095–2102.Kuemmerle-Deschner JB, Hachulla E, Gartwright R, Hawkins PN, Tran TA. Two year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of Canakinumab in pts with cryopyrin associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70(12):2095–2102.Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, Ferreira A, Lheritier K, Patel N, Preiss R, Hawkins PN. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a doubleblind placebo-controlled randomized withdrawal study. Arthritis Res Ther. 2011; 13: R202.Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, Ferreira A, Lheritier K, Patel N, Preiss R, Hawkins PN. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a doubleblind placebo-controlled randomized withdrawal study. Arthritis Res Ther. 2011; 13: R202.Goldbach-Mansky R, Sibley C, Felix S et al. Efficacy and safety of canacinumab in patients with NOMID/CINCA. Ann Rheum Dis. 2012;71(Suppl.3):291.Goldbach-Mansky R, Sibley C, Felix S et al. Efficacy and safety of canacinumab in patients with NOMID/CINCA. Ann Rheum Dis. 2012;71(Suppl.3):291.Caorsi R, Lepore L, Zulian F, Hawkins PN, Tran TA. The schedule of administration of Canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther. 2013;15(1): R33.Caorsi R, Lepore L, Zulian F, Hawkins PN, Tran TA. The schedule of administration of Canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther. 2013;15(1): R33.Imagawa T, Nishikomori R, Takada H. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin associated periodic syndrome as established in the first openlabel, phase-3 pivotal study (24-week results). Clin Exp Rheum. 2013;31:302–309.Imagawa T, Nishikomori R, Takada H. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin associated periodic syndrome as established in the first openlabel, phase-3 pivotal study (24-week results). Clin Exp Rheum. 2013;31:302–309.Russo RAG, Melo-Gomes S, Lachmann HJ, Wynne K, Rajput K, Eleftheriou D, Edelsten C, Hawkins PN, Brogan PA. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrinassociated periodic syndrome: a single center, real world experience. Rheumatology. 2014;53:665–670.Russo RAG, Melo-Gomes S, Lachmann HJ, Wynne K, Rajput K, Eleftheriou D, Edelsten C, Hawkins PN, Brogan PA. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrinassociated periodic syndrome: a single center, real world experience. Rheumatology. 2014;53:665–670.Sibley CH, Chioato A, Felix S., Colin L., Chakraborty A., Plass N., Rodriguez-Smith J. et al. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. Ann Rheum Dis. 2015;74(9):1714–1719. Doi: 10.1136/annrheumdis-2013-204877.Sibley CH, Chioato A, Felix S., Colin L., Chakraborty A., Plass N., Rodriguez-Smith J. et al. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. Ann Rheum Dis. 2015;74(9):1714–1719. Doi: 10.1136/annrheumdis-2013-204877.Hoffman H, Kuemmerle-Deschner J, Hawkins P, Colin L, Chakraborty A, Plass N, Rodriguez-Smith J, Brewer C, King K, Zalewski C, Kim HJ, Bishop R, Abrams K, Stone D, Chapelle D, Kost B, Snyder C, Butman JA, Wesley R, Goldbach-Mansky R. Safety of canacinumab in a large cohort of patients with cryopirin associated periodic syndrome: results from the confident registry. Arthritis Rheum. 2012;64(10):78.Hoffman H, Kuemmerle-Deschner J, Hawkins P, Colin L, Chakraborty A, Plass N, Rodriguez-Smith J, Brewer C, King K, Zalewski C, Kim HJ, Bishop R, Abrams K, Stone D, Chapelle D, Kost B, Snyder C, Butman JA, Wesley R, Goldbach-Mansky R. Safety of canacinumab in a large cohort of patients with cryopirin associated periodic syndrome: results from the confident registry. Arthritis Rheum. 2012;64(10):78.Gattorno M, Obici L, Meini A, Barcellona R, Speziale A, Joubert Y, Junge G. Efficacy and safety of Canakinumab in patients with TNF receptor associated periodic syndrome. Arthritis Rheum. 2012;64(10):322.Gattorno M, Obici L, Meini A, Barcellona R, Speziale A, Joubert Y, Junge G. Efficacy and safety of Canakinumab in patients with TNF receptor associated periodic syndrome. Arthritis Rheum. 2012;64(10):322.Vanderschueren S, Knockaert D. Canakinumab in Schnitzler syndrome Semin. Arthritis Rheum. 2013;42(4):413–416.Vanderschueren S, Knockaert D. Canakinumab in Schnitzler syndrome Semin. Arthritis Rheum. 2013;42(4):413–416.Koning H, Schalkwijk J, Jos WM, Simon A. Successful canakinumab treatment identifies IL-1 as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol. 2011;128(6):1352–1354.Koning H, Schalkwijk J, Jos WM, Simon A. Successful canakinumab treatment identifies IL-1 as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol. 2011;128(6):1352–1354.Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Nigrovic PA, Robinson AB, Vehe RK. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res. (Hoboken). 2013;65:1551–1563.Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Nigrovic PA, Robinson AB, Vehe RK. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res. (Hoboken). 2013;65:1551–1563.Vastert SJ, Kuis W, Grom AA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol. 2009;23(5):655–64. Doi: 10.1016/j.berh.2009.08.003.Vastert SJ, Kuis W, Grom AA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol. 2009;23(5):655–64. Doi: 10.1016/j.berh.2009.08.003.Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. New Engl J Med. 2012; 367(25):2396–2406.Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. New Engl J Med. 2012; 367(25):2396–2406.Brunner H, Ruperto N, Konea-Paut I, Magnusson B, Ozen S, Sztajnbok F. et al. An exploratory analysis of predictors of response from 12-weeks of canakinumab therapy in patients with active systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014; 66(11):930–413.Brunner H, Ruperto N, Konea-Paut I, Magnusson B, Ozen S, Sztajnbok F. et al. An exploratory analysis of predictors of response from 12-weeks of canakinumab therapy in patients with active systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014; 66(11):930–413.Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JM, Cohen N, Pope TD, Furst DE. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and metaanalysis of randomized trials. Rheumatology. 2015; pii: kev382. [Epub ahead of print].Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JM, Cohen N, Pope TD, Furst DE. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and metaanalysis of randomized trials. Rheumatology. 2015; pii: kev382. [Epub ahead of print].

The authors declare that there are no conflicts of interest present.